IE
SONN

Israel Englander’s Sonnet BioTherapeutics SONN Stock Holding History

Israel Englander’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16
Closed -$11K – 7461
2022
Q2 		$11K Sell
16
-142
-90% -$102K ﹤0.01% 6650
2022
Q1 		$147K Buy
+158
New +$134K ﹤0.01% 5979
2015
Q4 		– Hold
0
– -$227K – 3742
2015
Q3 		– Hold
0
– – – 3059
2015
Q2 		– Hold
0
– – – 2637
2015
Q1 		– Hold
0
– – – 2717
2014
Q4 		– Hold
0
– – – 3185
2014
Q3 		– Hold
0
– – – 2795
2014
Q2 		– Hold
0
– – – 2506
2014
Q1 		– Hold
0
– – – 2333
2013
Q4 		– Hold
0
– – – 2161
2013
Q3 		– Hold
0
– – – 2065
2013
Q2 		– Hold
0
– – – 2189

Other funds holding SONN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Israel Englander's SONN Position: Q3 2022 in Review

Israel Englander sold out of Sonnet BioTherapeutics (SONN) in Q3 2022, closing a stake of 16 shares — an estimated $11K sold.

Israel Englander first reported a position in SONN in Q1 2022 and held it in 2 quarters. The position peaked at $147K in Q1 2022. 10 funds tracked by Wall St. Rank hold SONN as of Q3 2022.

  • Israel Englander reported no remaining Sonnet BioTherapeutics position as of Q3 2022 after selling out during the quarter.
  • Israel Englander sold 16 Sonnet BioTherapeutics shares in Q3 2022, an estimated $11K.
  • Israel Englander first reported a position in Sonnet BioTherapeutics in Q1 2022 and held it in 2 quarters.
  • Israel Englander's Sonnet BioTherapeutics position peaked at $147K in Q1 2022.
  • 10 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.